



MAGLUMI® Growth Hormone (CLIA)

INTENDED USE

The kit is an *in vitro* chemiluminescence immunoassay for the quantitative determination of Growth Hormone (GH) in human serum and plasma using the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer and Biolumi series Integrated System, and the assay is used for an aid in assessment of pituitary gland and disorder of growth hormone caused by non-pituitary disease.

SUMMARY

Growth hormone (GH) belongs to a superfamily of cytokines¹. GH is considered to be the central endocrine regulator of growth². Its actions involve multiple organs and systems, affecting postnatal longitudinal growth as well as protein, lipid, and carbohydrate metabolism³. GH is a heterogeneous protein composed of several molecular isoforms¹. GH 22 kDa is considered the classic or typical GH and is the most abundant isoform in the circulation (more than 90% of total GH). This isoform is composed of 1–191 amino acids. This predominant GH form is growth-promoting and influences energetic and anabolic lipolysis and other metabolic processes. The GH 20 kDa, which represents about 10% of the total circulating GH, is different from the 22 kDa form because it lacks amino acid residues 32–46⁴.

GH is secreted in a pulsatile fashion from the pituitary somatotrophs under the positive and negative influence of the hypothalamic hormones GH-releasing hormone (GHRH) and somatostatin, respectively⁵. GH secretion is under the influence of additional hormonal signals, and sex steroids and thyroid hormone stimulate, whereas glucocorticoids inhibit, GH secretion⁶. GH secretion has peaks (higher at night than during the day and mediated by a reduction in tonic hypothalamic somatostatin secretion) and troughs⁵. The changes in GH and IGF-I secretion that occur with aging are paralleled by a progressive loss of muscle mass and strength, a decline in physical performance, an increase in body fat, and a decrease in bone mineral density (BMD)⁶. In healthy adults, there are gender differences in the amount and pattern of GH secretion. Women in general have a higher level of GH secretion than men, but the normal range of serum IGF-I concentrations is similar in adult men and women, possibly implying some degree of GH resistance in women⁷. Pregnant women have elevated levels of serum growth hormone⁸.

GH acts on multiple cell types, tissues and organs, but for growth, its main targets are the liver and the epiphyseal plates in long bones and spine⁵. GH hypersecretion results in gigantism or acromegaly, a condition associated with significant morbidity and mortality, while GH deficiency results in growth retardation in children and the GH deficiency syndrome in adults³. Gigantism refers to GH excess that occurs during childhood when open epiphyseal growth plates allow for excessive linear growth, whereas acromegaly indicates the same phenomenon occurring in adulthood⁹. Hyposecretion of GH during early development, or no GH production due to GH gene mutations result in dwarfism⁷.

GH-deficiency (GHD) is associated with an increased prevalence of atherosclerosis caused by an increased prevalence of atherosclerotic risk factors, such as alterations of body composition, lipid profile, and coagulation pattern. Additionally, it has been found that acromegaly also raises the risk of atherosclerosis¹⁰. Severe GHD in adults is associated with adverse changes in body composition, lipid metabolism, insulin sensitivity, and exercise capacity⁶. Measuring the concentration of GH in blood samples taken during dynamic tests represents the basis for diagnosis of growth hormone related disorders, namely growth hormone deficiency and growth hormone excess¹¹. GH and IGF-I measurements are widely used in the diagnosis of disorders of GH secretion, evaluation of children with short stature from multiple causes, management of disorders that lead to nutritional insufficiency or catabolism, and monitoring both GH and IGF-I replacement therapy¹².

TEST PRINCIPLE

Sandwich chemiluminescence immunoassay.

The sample, ABEI labeled with GH monoclonal antibody, buffer, magnetic microbeads coated with another GH monoclonal antibody are mixed thoroughly and incubated, reacting to form sandwich complexes. After precipitation in a magnetic field, the supernatant is decanted and then a wash cycle is performed. Subsequently, the Starter 1+2 are added to initiate a chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLUs), which is proportional to the concentration of GH present in the sample.

REAGENTS

Kit Contents

Component	Description	100 tests/kit	50 tests/kit	30 tests/kit
Magnetic Microbeads	Magnetic microbeads coated with GH monoclonal antibody (~8.00 µg/mL) in PBS buffer, NaN ₃ (<0.1%).	2.5 mL	1.5 mL	1.0 mL
Calibrator Low	A low concentration of GH antigen in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Calibrator High	A high concentration of GH antigen in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Buffer	Tris-HCl buffer, NaN ₃ (<0.1%).	6.5 mL	4.0 mL	3.0 mL
ABEI Label	ABEI labeled with GH monoclonal antibody (~0.333 µg/mL) in Tris-HCl buffer, NaN ₃ (<0.1%).	7.5 mL	4.5 mL	3.3 mL
Control 1	A low concentration of GH antigen (3.00 ng/mL) in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL
Control 2	A high concentration of GH antigen (10.0 ng/mL) in PBS buffer, NaN ₃ (<0.1%).	1.0 mL	1.0 mL	1.0 mL

All reagents are provided ready-to-use.

Warnings and Precautions

- For *in vitro* diagnostic use.
- For professional use only.
- Exercise the normal precautions required for handling all laboratory reagents.
- Personal protective measures should be taken to prevent any part of the human body from contacting samples, reagents, and controls, and should comply with local operating requirements for the assay.
- A skillful technique and strict adherence to the package insert are necessary to obtain reliable results.
- Do not use kit beyond the expiration date indicated on the label.
- Do not interchange reagent components from different reagents or lots.
- Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).
- All waste associated with biological samples, biological reagents and disposable materials used for the assay should be considered potentially infectious and should be disposed of in accordance with local guidelines.
- This product contains sodium azide. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. Immediately after disposal, flush with a large volume of water to prevent azide build-up. For additional information, see Safety Data Sheets available for professional user on request.

Note: If any serious incident has occurred in relation to the device, please report to Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) or our authorized representative and the competent authority of the Member State in which you are established.

Reagent Handling

- To avoid contamination, wear clean gloves when operating with a reagent kit and sample. When handling reagent kit, replace the gloves that have been in contact with samples, since introduction of samples will result in unreliable results.
- Do not use kit in malfunction conditions; e.g., the kit leaking at the sealing film or elsewhere, obviously turbid or precipitation is found in reagents (except for Magnetic Microbeads) or control value is out of the specified range repeatedly. When kit in malfunction conditions, please contact Snibe or our authorized distributor.
- To avoid evaporation of the liquid in the opened reagent kits in refrigerator, it is recommended that the opened reagent kits to be sealed with reagent seals contained within the packaging. The reagent seals are single use, and if more seals are needed, please contact Snibe or our authorized distributor.
- Over time, residual liquids may dry on the septum surface. These are typically dried salts and have no effect on assay efficacy.
- Use always the same analyzer for an opened reagent integral.
- For magnetic microbeads mixing instructions, refer to the Preparation of the Reagent section of this package insert.
- For further information about the reagent handling during system operation, please refer to Analyzer Operating Instructions.

Storage and Stability

- Do not freeze the integral reagents.
- Store the reagent kit upright to ensure complete availability of the magnetic microbeads.



130270001M: 100 tests/kit
130670001M: 50 tests/kit
130770001M: 30 tests/kit

- Protect from direct sunlight.

Stability of the Reagents	
Unopened at 2-8°C	until the stated expiration date
Opened at 2-8°C	6 weeks
On-board	4 weeks

Stability of Controls	
Unopened at 2-8°C	until the stated expiration date
Opened at 10-30°C	6 hours
Opened at 2-8°C	6 weeks
Frozen at -20°C	3 months
Frozen and thawed cycles	no more than 3 times

SPECIMEN COLLECTION AND PREPARATION

Specimen Types

Only the specimens listed below were tested and found acceptable.

Specimen Types	Collection Tubes
Serum	Tubes without additive/accessory, or tubes containing clot activator or clot activator with gel.
Plasma	K2-EDTA

- The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. Follow tube manufacturers' instructions carefully when using collection tubes.

Specimen Conditions

- Do not use heat-inactivated samples or grossly hemolyzed/hyperlipidaemia specimens and specimens with obvious microbial contamination.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some serum specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the serum specimen is centrifuged before a complete clotting, the presence of fibrin may cause erroneous results.
- Samples must be free of fibrin and other particulate matter.
- To prevent cross contamination, use of disposable pipettes or pipette tips are recommended.

Preparation for Analysis

- Inspect all specimens for foam. Remove foam with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.
- Frozen specimens must be completely thawed before mixing. Mix thawed specimens thoroughly by low speed vortexing or by gently inverting. Visually inspect the specimens. If layering or stratification is observed, mix until specimens are visibly homogeneous. If specimens are not mixed thoroughly, inconsistent results may be obtained.
- Specimens should be free of fibrin, red blood cells, or other particulate matter. Such specimens may give reliable results and must be centrifuged prior to testing. Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
- The sample volume required for a single determination of this assay is 20 µL.

Specimen Storage

Specimens removed from the separator, red blood cells or clot may be stored up to 24 hours at 10-30°C or 7 days at 2-8°C, or 6 months frozen at -20°C. Frozen specimens subjected to up to 3 freeze/thaw cycles have been evaluated.

Specimen Shipping

- Package and label specimens in compliance with applicable local regulations covering the transport of clinical specimens and infectious substances.
- Do not exceed the storage limitations listed above.

Specimen Dilution

- Samples, with GH concentrations above the analytical measuring interval, can be diluted with manual dilution procedure. The recommended dilution ratio is 1:10. The concentration of the diluted sample must be >5 ng/mL.
- For manual dilution, multiply the result by the dilution factor.
- Please choose applicable diluents or ask Snibe for advice before manual dilution.

PROCEDURE

Materials Provided

Growth Hormone (CLIA) assay, control barcode labels.

Materials Required (But Not Provided)

- General laboratory equipment.
- Fully-auto chemiluminescence immunoassay analyzer Maglumi 600, Maglumi 800, Maglumi 1000, Maglumi 2000, Maglumi 2000 Plus, Maglumi 4000, Maglumi 4000 Plus, MAGLUMI X8, MAGLUMI X3, MAGLUMI X6 or Integrated System Biolumi 8000, Biolumi CX8.
- Additional accessories of test required for the above analyzers include Reaction Module, Starter 1+2, Wash Concentrate, Light Check, Tip, and Reaction Cup. Specific accessories and accessories' specification for each model refer to corresponding Analyzer Operating Instructions.
- Please use accessories specified by Snibe to ensure the reliability of the test results.

Assay Procedure

Preparation of the Reagent

- Take the reagent kit out of the box and visually inspect the integral vials for leaking at the sealing film or elsewhere. If there is no leakage, please tear off the sealing film carefully.
- Open the reagent area door; hold the reagent handle to get the RFID label close to the RFID reader (for about 2s); the buzzer will beep; one beep sound indicates successful sensing.
- Keeping the reagent straight insert to the bottom along the blank reagent track.
- Observe whether the reagent information is displayed successfully in the software interface, otherwise repeat the above two steps.
- Resuspension of the magnetic microbeads takes place automatically when the kit is loaded successfully, ensuring the magnetic microbeads are totally resuspended homogenous prior to use.

Assay Calibration

- Select the assay to be calibrated and execute calibration operation in reagent area interface. For specific information on ordering calibrations, refer to the calibration section of Analyzer Operating Instructions.
- Execute recalibration according to the calibration interval required in this package insert.

Quality Control

- When new lot used, check or edit the quality control information.
- Scan the control barcode, choose corresponding quality control information and execute testing. For specific information on ordering quality controls, refer to the quality control section of the Analyzer Operating Instructions.

Sample Testing

- After successfully loading the sample, select the sample in interface and edit the assay for the sample to be tested and execute testing. For specific information on ordering patient specimens, refer to the sample ordering section of the Analyzer Operating Instructions.

To ensure proper test performance, strictly adhere to Analyzer Operating Instructions.

Calibration

Traceability: This method has been standardized against the WHO 2nd International Standard 98/574.

Test of assay specific calibrators allows the detected relative light unit (RLU) values to adjust the master curve.

Recalibration is recommended as follows:

- Whenever a new lot of Reagent or Starter 1+2 is used.

- Every 28 days.
- The analyzer has been serviced.
- Control values lie outside the specified range.

Quality Control

Controls are recommended for the determination of quality control requirements for this assay and should be run in singlicate to monitor the assay performance. Refer to published guidelines for general quality control recommendations, for example Clinical and Laboratory Standards Institute (CLSI) Guideline C24 or other published guidelines¹³.

Quality control is recommended once per day of use, or in accordance with local regulations or accreditation requirements and your laboratory's quality control procedures, quality control could be performed by running the GH assay:

- Whenever the kit is calibrated.
- Whenever a new lot of Starter 1+2 or Wash Concentrate is used.

Controls are only applicable with MAGLUMI and Biolumi systems and only used matching with the same top seven LOT numbers of corresponding reagents. For each target value and range refer to the label.

The performance of other controls should be evaluated for compatibility with this assay before they are used. Appropriate value ranges should be established for all quality control materials used.

Control values must lie within the specified range, whenever one of the controls lies outside the specified range, calibration should be repeated and controls retested. If control values lie repeatedly outside the predefined ranges after successful calibration, patient results must not be reported and take the following actions:

- Verify that the materials are not expired.
- Verify that required maintenance was performed.
- Verify that the assay was performed according to the package insert.
- If necessary, contact Snibe or our authorized distributors for assistance.

If the controls in kit are not enough for use, please order Growth Hormone (CLIA) Controls (REF: 160201467MT) from Snibe or our authorized distributors for more.

RESULTS

Calculation

The analyzer automatically calculates the GH concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in ng/mL. For further information please refer to the Analyzer Operating Instructions.

Conversion factors: ng/mL x 3.0 = mIU/L.

Interpretation of Results

The expected range for the GH assay was obtained by testing 854 apparently healthy individuals in China, gave the following expected value:

Gender	Age (years)	Median (ng/mL)	5 th percentile (ng/mL)	95 th percentile (ng/mL)
Men (N=448)	0-10	0.863	0.085	6.61
	11-19	0.345	0.071	11.2
	20-79	0.123	<0.010	2.54
Women (N=406)	0-10	0.744	0.113	7.95
	11-20	0.454	0.119	8.30
	21-77	0.906	0.116	9.17

Results may differ between laboratories due to variations in population and test method. It is recommended that each laboratory establish its own reference interval.

LIMITATIONS

- Results should be used in conjunction with patient's medical history, clinical examination and other findings.
- If the GH results are inconsistent with clinical evidence, additional testing is needed to confirm the result.
- The assay is mainly used to aid in assessment of individuals with suspected or confirmed growth hormone disorders caused by pituitary and non-pituitary diseases.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits which employ mouse monoclonal antibodies^{14,15}. Additional information may be required for diagnosis.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with *in vitro* immunoassays. Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous values may be observed¹⁶.
- Bacterial contamination or heat inactivation of the specimens may affect the test results.
- GH concentrations fluctuate throughout the day. GH levels may be elevated in the presence of malnutrition^{5,17,18}.
- As GH levels remain elevated with pegvisomant therapy, measuring GH in patients receiving pegvisomant should not be done¹⁹.

SPECIFIC PERFORMANCE CHARACTERISTICS

Representative performance data are provided in this section. Results obtained in individual laboratories may vary.

Precision

Precision was determined using the assay, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): duplicates at two independent runs per day for 5 days at three different sites using three lots of reagent kits (n = 180). The following results were obtained:

Sample	Mean (ng/mL) (n=180)	Within-Run		Between-Run		Reproducibility	
		SD (ng/mL)	%CV	SD (ng/mL)	%CV	SD (ng/mL)	%CV
Serum Pool 1	3.083	0.088	2.85	0.044	1.43	0.113	3.67
Serum Pool 2	10.393	0.260	2.50	0.126	1.21	0.366	3.52
Serum Pool 3	31.387	0.424	1.35	0.305	0.97	0.753	2.40
Plasma Pool 1	3.057	0.089	2.91	0.063	2.06	0.121	3.96
Plasma Pool 2	9.889	0.229	2.32	0.134	1.36	0.325	3.29
Plasma Pool 3	29.130	0.429	1.47	0.143	0.49	0.749	2.57
Control 1	2.982	0.098	3.29	0.043	1.44	0.128	4.29
Control 2	10.097	0.249	2.47	0.165	1.63	0.384	3.80

Linear Range

0.050-50.0 ng/mL (defined by the Limit of Quantitation and the maximum of the master curve).

Reportable Interval

0.030-500 ng/mL (defined by the Limit of Detection and the maximum of the master curve*Recommended Dilution Ratio).

Analytical Sensitivity

Limit of Blank (LoB) =0.010 ng/mL.

Limit of Detection (LoD) =0.030 ng/mL.

Limit of Quantitation (LoQ) =0.050 ng/mL.

Analytical Specificity

Interference

Interference was determined using the assay, three samples containing different concentrations of analyte were spiked with potential endogenous and exogenous interferents in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Interference	No interference up to	Interference	No interference up to
Hemoglobin	2000 mg/dL	Rheumatoid factor	600 IU/mL
Intralipid	5000 mg/dL	Human albumin	12 g/dL
Bilirubin	40 mg/dL	K2-EDTA	22.75 µmol/mL
HAMA	40 ng/mL		
ANA	398 AU/mL	Biotin	0.5 mg/dL

Cross-Reactivity

Cross-reactivity was determined using the assay, three samples containing different concentrations of analyte were spiked with potential cross-reactant in a protocol (EP7-A2) of the CLSI. The measurement deviation of the interference substance is within ±10%. The following results were obtained:

Cross-reactant	No interference up to	Cross-reactant	No interference up to
TSH	500 µIU/mL	F-β-HCG	280 ng/mL
FSH	10000 mIU/mL	Prolactin	40000 ng/mL
LH	40000 mIU/mL	HPL	10000 ng/mL
HCG	125000 mIU/mL	IGF-I	900 ng/mL

High-Dose Hook

No high-dose hook effect was seen for GH concentrations up to 2000 ng/mL.

Method Comparison

A comparison of the GH assay with a commercially available immunoassay, gave the following correlations (ng/mL):

Number of samples measured: 158

Passing-Bablok: y=1.0001x-0.0010, r=0.964.

The clinical specimen concentrations were between 0.050 and 49.46 ng/mL.

REFERENCES

1. Ribeiro de Oliveira Longo Schweizer J, Ribeiro-Oliveira Jr A, Bidlingmaier M. Growth hormone: isoforms, clinical aspects and assays interference[J]. Clinical diabetes and endocrinology, 2018, 4(1): 1-113.
2. Okada S, Kopchick J J. Biological effects of growth hormone and its antagonist[J]. Trends in molecular medicine, 2001, 7(3): 126-132.
3. Ayuk J, Sheppard M C. Growth hormone and its disorders[J]. Postgraduate medical journal, 2006, 82(963): 24-30.
4. Elio F, De Filippis V, Gatti R, et al. Growth hormone isoforms and segments/fragments: molecular structure and laboratory measurement[J]. Clinica chimica acta, 2006, 364(1-2): 67-76.
5. Ranke M B, Wit J M. Growth hormone—past, present and future[J]. Nature Reviews Endocrinology, 2018, 14(5): 285-300.
6. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton[J]. Endocrine reviews, 2008, 29(5): 535-559.
7. Nilsson A G. Effects of growth hormone replacement therapy on bone markers and bone mineral density in growth hormone-deficient adults[J]. Hormone Research in Paediatrics, 2000, 54(Suppl. 1): 52-57.
8. Oscar, A, Kletzky, et al. Dynamics of human chorionic gonadotropin, prolactin, and growth hormone in serum and amniotic fluid throughout normal human pregnancy[J]. American Journal of Obstetrics and Gynecology, 1985, 151(7):878-884.
9. Eugster E A, Pescovitz O H. Gigantism[J]. The Journal of Clinical Endocrinology & Metabolism, 1999, 84(12): 4379-4384.
10. Caicedo D, Diaz O, Devesa P, et al. Growth hormone (GH) and cardiovascular system[J]. International journal of molecular sciences, 2018, 19(1): 290.
11. Bidlingmaier M, Freda P U. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences[J]. Growth Hormone & IGF Research, 2010, 20(1): 19-25.
12. Clemmons D R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays[J]. Clinical chemistry, 2011, 57(4): 555-559.
13. CLSI. Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions. 4th ed. CLSI guideline C24. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
14. Robert W. Schroff, Kenneth A. Foon, Shannon M. Beatty, et al. Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy[J]. Cancer Research, 1985, 45(2):879-85.
15. Primus F J, Kelley E A, Hansen H J, et al. "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy[J]. Clinical Chemistry, 1988, 34(2):261-264.
16. Boscatto L M, Stuart M C. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988;34(1):27-33.
17. Freda P U. Monitoring of acromegaly: what should be performed when GH and IGF - 1 levels are discrepant?[J]. Clinical endocrinology, 2009, 71(2): 166-170.
18. Katznelson L, Atkinson J L D, Cook D M, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update[J]. Endocrine practice, 2011, 17: 1-44.
19. Melmed S, Bronstein M D, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes[J]. Nature Reviews Endocrinology, 2018, 14(9): 552-561.

SYMBOLS EXPLANATIONS

	Consult instructions for use		Manufacturer
	Temperature limit (Store at 2-8°C)		Use-by date
	Contains sufficient for n > tests		Keep away from sunlight
	This way up		Authorized representative in the European Community
	In vitro diagnostic medical device		Kit component
	Catalogue number		Batch code
	CE marking with notified body ID number		

MAGLUMI® and Biolumi® are trademarks of Snibe. All other product names and trademarks are the property of their respective owners.

	Shenzhen New Industries Biomedical Engineering Co., Ltd. No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China Tel: +86-755-21536601 Fax: +86-755-28292740
	Shanghai International Holding Corp. GmbH (Europe) Eiffestrasse 80, 20537 Hamburg, Germany Tel: +49-40-2513175 Fax: +49-40-255726